First ever inhalable gene therapy for cancer gets fast-tracked by FDA
SMRTR summary
The FDA fast-tracked approval for the first inhalable gene therapy for lung cancer after clinical trials showed it shrank tumors in three of eleven patients with advanced disease. The treatment uses a modified herpes virus to deliver immune-boosting genes directly into lung cells through inhalation, helping restore natural tumor-fighting proteins that cancer often depletes.
SMRTR provides this summary for quick context. The original article belongs to Hacker News.
Read the original article